172 related articles for article (PubMed ID: 9717816)
1. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
[TBL] [Abstract][Full Text] [Related]
2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
3. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
Delsite R; Djakiew D
J Androl; 1996; 17(5):481-90. PubMed ID: 8957691
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
[TBL] [Abstract][Full Text] [Related]
6. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
Pinski J; Weeraratna A; Uzgare AR; Arnold JT; Denmeade SR; Isaacs JT
Cancer Res; 2002 Feb; 62(4):986-9. PubMed ID: 11861369
[TBL] [Abstract][Full Text] [Related]
7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
8. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
Maeda H; Hori S; Nishitoh H; Ichijo H; Ogawa O; Kakehi Y; Kakizuka A
Cancer Res; 2001 Jul; 61(14):5432-40. PubMed ID: 11454688
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
11. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
Camoratto AM; Jani JP; Angeles TS; Maroney AC; Sanders CY; Murakata C; Neff NT; Vaught JL; Isaacs JT; Dionne CA
Int J Cancer; 1997 Aug; 72(4):673-9. PubMed ID: 9259409
[TBL] [Abstract][Full Text] [Related]
12. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
[TBL] [Abstract][Full Text] [Related]
13. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
14. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
15. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts.
Samsel L; Zaidel G; Drumgoole HM; Jelovac D; Drachenberg C; Rhee JG; Brodie AM; Bielawska A; Smyth MJ
Prostate; 2004 Mar; 58(4):382-93. PubMed ID: 14968439
[TBL] [Abstract][Full Text] [Related]
16. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
18. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
Spruce BA; Campbell LA; McTavish N; Cooper MA; Appleyard MV; O'Neill M; Howie J; Samson J; Watt S; Murray K; McLean D; Leslie NR; Safrany ST; Ferguson MJ; Peters JA; Prescott AR; Box G; Hayes A; Nutley B; Raynaud F; Downes CP; Lambert JJ; Thompson AM; Eccles S
Cancer Res; 2004 Jul; 64(14):4875-86. PubMed ID: 15256458
[TBL] [Abstract][Full Text] [Related]
19. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
20. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
